Private Equity focused on investment and operations within the Life Science industry faces significant compliance, operational and business risk due to the heavily regulated nature of the investment targets and portfolio companies. The following compliance risk priorities reflect risks across the Life Science industry, including technology services and workflow optimization, clinical trial operations, solutions and support, drug, biologic and device manufacturing, drug development and formulation, strategic regulatory and economic consulting services, packing and component manufacturing, marketing and commercialization services, and medical writing and communications.
Read the full article: Life Science Private Equity Risk //
Source: https://www.lexology.com/library/detail.aspx?g=73e741c4-314d-45d4-a0ca-f2358a642547